Thank you, Madam Chair, and thank you to the witnesses for being with us this afternoon.
I'm going to begin with Dr. Michaud.
I enjoyed your presentation. With regard to BioCanRx, in your remarks, you said, “progress is real” and it leads to “real-world outcomes”. You said that we need to harness our scientific strengths for our overall sovereignty. Ultimately, the question that we need to ask is, with those dollars that we spend—I think it's over $10 billion in public research funding for scientific research—whether the investment is, in your case, reaching the patient.
I just read an article that was published in the Hill Times, which revealed that ISED had informed organizations such as yours that the strategic science fund would be cutting $20 million from the $800-million fund as part of the government's overall expenditure review decision.
It's interesting that we're doing a study on governance and accountability of federal science policy and institutions. As part of the strategic science fund, one of the means of accountability where the government is dealing with the not-for-profit sectors is they put in place accountability measures, performance targets and funding for projects. They ask whether the not-for-profits are getting results for those projects. To your point, Dr. Michaud, is that funding reaching the patient? For example, one of the means of accountability is the contribution agreements that are put in place by the government. Your funding will be cut in the last year of that contribution agreement.
My understanding is they're legally binding documents. How is it that the government can pull funding in your last year as part of that contribution agreement?
